Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A chemogenomic approach to identify personalized therapy for patients with relapse or refractory acute myeloid leukemia: results of a prospective feasibility study.

Blood cancer journal - 3 Jun 2020

Collignon A, Hospital M A, Montersino C, Courtier F, Charbonnier A, Saillard C, D'Incan E, Mohty B, Guille A, Adelaïde J, Carbuccia N, Garnier S, Mozziconacci M J, Zemmour C, Pakradouni J, Restouin A, Castellano R, Chaffanet M, Birnbaum D, Collette Y, Vey N

Abstract excerpt

Targeted next-generation sequencing (tNGS) and ex vivo drug sensitivity/resistance profiling (DSRP) have laid foundations defining the functional genomic landscape of acute myeloid leukemia (AML) and premises of personalized medicine to guide treatment options for patients with aggressive and/or chemorefractory hematological malignancies. Here, we have assessed the feasibility of a tailored treatment strategy...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Feasibility Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genomics

Share to High-Throughput Nucleotide Sequencing

Share to Leukemia, Myeloid, Acute

Share to Molecular Targeted Therapy

Share to Neoplasm Recurrence, Local

Share to Precision Medicine

Source

Open in PubMed Open full text

Identifiers

PMID: 32488055
DOI: 10.1038/s41408-020-0330-5
PMCID: PMC7266815

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A chemogenomic approach to identify personalized therapy for patients with relapse or refractory acute myeloid leukemia: results of a prospective feasibility study.PMID 32488055Read ↗

Monitoring therapy responses at the leukemic subclone level by ultra-deep amplicon resequencing in acute myeloid leukemia.Semantic proximity Read ↗

Advancing Chemogenomic Strategies for Functional Precision Medicine in Relapsed/Refractory T-ALL and ETP-ALL: TheGimema ALL2720 TrialSemantic proximity Read ↗

New drugs for acute myeloid leukemia inspired by genomics and when to use themSemantic proximity Read ↗

Combining clinical and molecular data for personalized treatment in acute myeloid leukemia: A machine learning approach.Semantic proximity Read ↗

Improving the prediction of acute myeloid leukaemia outcomes by complementing mutational profiling with ex vivo chemosensitivity.Semantic proximity Read ↗

Integrating ex vivo drug sensitivity and genetic mutation analysis improves prediction of chemotherapy response in acute myeloid leukemia.Semantic proximity Read ↗

Machine Learning for Predicting Therapeutic Outcomes in Acute Myeloid Leukemia PatientsSemantic proximity Read ↗

Single-cell landscape of innate and acquired drug resistance in acute myeloid leukemiaSemantic proximity Read ↗

Network-based analysis with primary cells reveals drug response landscape of acute myeloid leukemia.Semantic proximity Read ↗

Clinical Forecasting using <i>Ex Vivo</i> Drug Sensitivity Profiling of Acute Myeloid LeukemiaSemantic proximity Read ↗

Mutation Patterns Predict Drug Sensitivity in Acute Myeloid LeukemiaSemantic proximity Read ↗

Ex Vivo Drug Responses and Molecular Profiles of 597 Pediatric Acute Lymphoblastic Leukemia PatientsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.